A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation

Epilepsia. 2008 Feb;49(2):248-55. doi: 10.1111/j.1528-1167.2007.01384.x. Epub 2007 Oct 15.

Abstract

Purpose: New treatments are needed for status epilepticus (SE) that is refractory to drugs modulating GABA(A) receptors, and NMDA receptor antagonists are candidate drugs.

Methods: Clinically available NMDA receptor antagonist ketamine was tested for effectiveness in terminating prolonged SE induced by a combination of lithium and pilocarpine. Animals were treated 10 min after first grade 5 behavioral seizure (Racine scoring scale) by intraperitoneal administration of ketamine, diazepam, or saline. Seizure termination was determined by electroencephalogram (EEG) recordings from the hippocampus and the cortex.

Results: Animals treated with normal saline or either 20 mg/kg diazepam, or 50 mg/kg ketamine continued in SE for the next 300 min. However, combined treatment with diazepam and ketamine rapidly terminated prolonged cholinergic stimulation-induced SE. Detailed study of dose response relationships demonstrated that diazepam enhanced efficacy and potency of ketamine in terminating SE.

Discussion: This study demonstrated synergistic action of diazepam and ketamine in terminating SE. It suggests that a ketamine-diazepam combination might be a clinically useful therapeutic option for the treatment of refractory SE.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / physiopathology
  • Diazepam / pharmacology
  • Diazepam / therapeutic use*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Drug Therapy, Combination
  • Electroencephalography / statistics & numerical data
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Hippocampus / drug effects
  • Hippocampus / physiopathology
  • Ketamine / pharmacology*
  • Ketamine / therapeutic use
  • Lithium Compounds*
  • Male
  • Muscarinic Agonists*
  • Pilocarpine*
  • Rats
  • Rats, Sprague-Dawley
  • Status Epilepticus / chemically induced*
  • Status Epilepticus / physiopathology
  • Status Epilepticus / prevention & control*
  • Treatment Outcome

Substances

  • Excitatory Amino Acid Antagonists
  • Lithium Compounds
  • Muscarinic Agonists
  • Pilocarpine
  • Ketamine
  • Diazepam